LVTX

LAVA Therapeutics NV (LVTX)

LAVA Therapeutics NV

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LVTX

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/01/25	22 : 07	Dow Jones News	Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	NASDAQ:LVTX	LAVA Therapeutics NV
2023/11/17	06 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LVTX	LAVA Therapeutics NV
2023/09/06	20 : 11	GlobeNewswire Inc.	LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:LVTX	LAVA Therapeutics NV
2023/08/23	05 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LVTX	LAVA Therapeutics NV
2023/08/22	20 : 00	GlobeNewswire Inc.	LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results	NASDAQ:LVTX	LAVA Therapeutics NV
2023/08/15	19 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LVTX	LAVA Therapeutics NV
2023/08/14	20 : 00	GlobeNewswire Inc.	LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/16	05 : 51	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/14	22 : 00	GlobeNewswire Inc.	LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/09	05 : 06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/08	20 : 00	GlobeNewswire Inc.	LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/06	19 : 02	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/06	07 : 31	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/02	08 : 38	Dow Jones News	Stocks to Watch: Lululemon, Lava Therapeutics, Tilly's, Oncorus	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/02	05 : 20	GlobeNewswire Inc.	LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development	NASDAQ:LVTX	LAVA Therapeutics NV
2023/06/01	21 : 09	GlobeNewswire Inc.	LAVA Therapeutics to Participate in the Jefferies Healthcare Conference	NASDAQ:LVTX	LAVA Therapeutics NV
2023/05/31	06 : 28	GlobeNewswire Inc.	LAVA Announces Annual Meeting of Shareholders	NASDAQ:LVTX	LAVA Therapeutics NV
2023/04/25	05 : 07	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/04/12	19 : 03	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/04/11	20 : 00	GlobeNewswire Inc.	LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results	NASDAQ:LVTX	LAVA Therapeutics NV
2023/03/09	22 : 05	GlobeNewswire Inc.	LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors	NASDAQ:LVTX	LAVA Therapeutics NV
2023/02/16	21 : 06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/02/16	21 : 00	GlobeNewswire Inc.	LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium	NASDAQ:LVTX	LAVA Therapeutics NV
2023/02/09	21 : 00	GlobeNewswire Inc.	LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference	NASDAQ:LVTX	LAVA Therapeutics NV
2023/02/06	21 : 07	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LVTX	LAVA Therapeutics NV
2023/02/06	21 : 00	GlobeNewswire Inc.	LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer	NASDAQ:LVTX	LAVA Therapeutics NV
2023/01/23	21 : 00	GlobeNewswire Inc.	LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium	NASDAQ:LVTX	LAVA Therapeutics NV
2023/01/07	03 : 07	GlobeNewswire Inc.	LAVA Therapeutics Announces Appointment of New Directors to the Board	NASDAQ:LVTX	LAVA Therapeutics NV
2023/01/03	21 : 00	GlobeNewswire Inc.	LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference	NASDAQ:LVTX	LAVA Therapeutics NV
2022/12/24	06 : 02	Edgar (US Regulatory)	Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)	NASDAQ:LVTX	LAVA Therapeutics NV